Trials / Unknown
UnknownNCT00017446
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Herbert Irving Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CP4071 in treating patients who have locally advanced or metastatic soft tissue sarcoma.
Detailed description
OBJECTIVES: * Determine the efficacy, in terms of response rate, of CP4071 in patients with previously treated, locally advanced or metastatic soft tissue sarcoma. * Determine the clinical toxic effects of this drug in these patients. OUTLINE: Patients receive oral CP4071 daily. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP4071 |
Timeline
- Start date
- 2000-10-01
- First posted
- 2003-06-12
- Last updated
- 2014-01-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00017446. Inclusion in this directory is not an endorsement.